QuADD (Quantum-Aided Drug Design) Platform
Quantum computing platform for drug discovery exploring 10^30 chemical space in hours
Platform · Cloud SaaSCompany source
Company profile
About Polaris Quantum Biotech
Polaris Quantum Biotech (PolarisQB) is a computational drug discovery company that leverages quantum computing technology to accelerate the identification of novel drug candidates. The company's proprietary Quantum-Aided Drug Design (QuADD) platform uses quantum annealing and quantum-inspired algorithms to solve ultra-large scale optimization problems in molecular design that are too complex for traditional computers. PolarisQB's approach enables exploration of chemical spaces exceeding 10^30 molecules—more than 20 orders of magnitude larger than conventional screening methods—in just hours rather than weeks or months. The platform performs multi-objective optimization at unprecedented scale and speed, applicable to any protein target without requiring training data. PolarisQB serves pharmaceutical companies, biotech firms, agricultural companies, and contract research organizations (CROs), offering solutions ranging from rapid lead generation to collaborative joint development programs. The company has demonstrated significant advantages over traditional computer-aided drug design (CADD), delivering stronger binding candidates with greater diversity and more drug-like properties in dramatically shorter timeframes. Based in Durham, North Carolina, PolarisQB partners with organizations across drug discovery, longevity research, and women's health to accelerate the path from target identification to viable drug candidates.
Company description Polaris Quantum Biotech official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Polaris Quantum Biotech?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Agriculture
- Biotech
- CROs
- Pharma
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsGreater China · Southeast Asia · USA
Company sourceOfficial website
Company milestones
Platform expansion
Selected as 2026 winner of Cleveland Clinic Quantum Innovation Catalyzer Program (April 2026); Announced exclusive representation agreement with PTG for Greater China and Southeast Asia (June 2026); Demonstrated advances in drug safety prediction with quantum-inspired AI (April 2026); Free trials of QuADD platform now available
Partnerships
Recorded partners
- Allosteric Bioscience
- Auransa
- Cleveland Clinic Quantum Innovation Catalyzer Program
- Phoremost
- POLARISQB TECHNOLOGIES GROUP PTE. LTD. (PTG)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
QuADD Collaborate
Joint development of best-fit molecules for new protein targets
Service · HybridCompany source
QuADD Rapid
Delivers 1-5k top-quality lead-like molecules for target protein binding pockets
Service · Cloud SaaSCompany source
QuADD Select
20-200 optimized molecules for your target protein, ready in 90 days
Service · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Quantum Computer Simulation of Protein Protonation.Journal of chemical theory and computation · Sep 12, 2023
Efficient Computation of the Electrostatic Component of Solvation Free Energy via a Two-Point Padé Approximation.Journal of chemical theory and computation · Aug 8, 2023
Deriving Immune-Modulating Peptides from Viral Serine Protease Inhibitors (Serpins).Methods in molecular biology (Clifton, N.J.) · Jan 1, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
2 days vs. 2 months
Time to identify drug candidates compared to traditional CADD
10^30 chemical space exploration
20+ orders of magnitude larger than traditional screening (10^10)
Stronger binding
Compared to traditional CADD methods
Greater diversity
More diverse molecular candidates than traditional methods
More drug-like properties
Improved drug-likeness compared to traditional CADD
Allosteric Bioscience
Discovery of novel molecules for Optimizing the Aging and Longevity Molecular Process
Explored previously undefined chemical space and discovered novel molecules much faster than expected
Auransa
Rapid identification of viable drug candidates for hard to tackle or neglected diseases affecting women's health
Significantly accelerated research timeline towards quality solutions
Phoremost
Matching full diversity of newly identified disease targets with rapid small molecule drug discovery
Partnership represents ultimate collaboration between biology and technology for logical and rapid drug finding
QuADD vs CADD Case Study
Comparative analysis of quantum-aided drug design versus traditional computer-aided drug design
2 days vs 2 months timeline, stronger binding, greater diversity, more drug-like molecules
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Polaris Quantum Biotech
Recent articles published on Polaris Quantum Biotech's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.